Glioma is the most common primary intracranial
tumor and is associated with very low survival rates. The development of reliable
biomarkers can help to elucidate the molecular mechanisms involved in
glioma development. Here the expression of ABCC8
mRNA, clinical characteristics, and survival information based on 1893
glioma samples from four independent databases were analyzed. The expression patterns of ABCC8
mRNA were compared by a Chi square test. The overall survival rate of
gliomas was evaluated according to the expression level of ABCC8
mRNA. The prognostic value of this marker in
gliomas was tested using Cox single factor and multi factor regression analyses. We found patients with low WHO grade, oligodendrocytoma, low molecular grade, IDH mutation, and 1p19q combined deletion had high ABCC8
mRNA expression. The patients with high expression of ABCC8
mRNA had longer survival. ABCC8
mRNA expression was a new independent prognostic index for
glioma.
Temozolomide chemotherapy was an independent index to prolong overall survival in high ABCC8
mRNA expression
glioma patients, whereas in patients with low expression, there was no significant difference. So ABCC8
mRNA expression could be an independent prognostic
indicator for
glioma patients and could predict the sensitivity of
glioma to
temozolomide.